CN104151262B - 4,5-bis-replaces-thiazolamine compound and preparation method thereof - Google Patents
4,5-bis-replaces-thiazolamine compound and preparation method thereof Download PDFInfo
- Publication number
- CN104151262B CN104151262B CN201410321285.9A CN201410321285A CN104151262B CN 104151262 B CN104151262 B CN 104151262B CN 201410321285 A CN201410321285 A CN 201410321285A CN 104151262 B CN104151262 B CN 104151262B
- Authority
- CN
- China
- Prior art keywords
- aminothiazole
- phenyl
- disubstituted
- compound
- methoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- -1 4,5-disubstituted-2-aminothiazole compound Chemical class 0.000 claims abstract description 111
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims abstract description 13
- 229940116357 potassium thiocyanate Drugs 0.000 claims abstract description 11
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims abstract description 10
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 8
- 239000002184 metal Substances 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- 239000012141 concentrate Substances 0.000 claims abstract description 6
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims abstract description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims abstract description 4
- 239000012044 organic layer Substances 0.000 claims abstract description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 18
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical group O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 12
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 7
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 5
- 239000012454 non-polar solvent Substances 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 claims description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 229960003280 cupric chloride Drugs 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 93
- 239000000047 product Substances 0.000 description 35
- 239000007787 solid Substances 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- SCBDPBCXUZBPGM-UHFFFAOYSA-N [2-amino-5-(furan-2-yl)-1,3-thiazol-4-yl]-phenylmethanone Chemical compound C=1C=COC=1C=1SC(N)=NC=1C(=O)C1=CC=CC=C1 SCBDPBCXUZBPGM-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 150000002611 lead compounds Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- DFWWBNHGVZGRDN-UHFFFAOYSA-N (2-amino-5-phenyl-1,3-thiazol-4-yl)-(4-methylphenyl)methanone Chemical compound CC1=CC=C(C(=O)C=2N=C(SC2C2=CC=CC=C2)N)C=C1 DFWWBNHGVZGRDN-UHFFFAOYSA-N 0.000 description 3
- JAWMKHVPLLQZHX-UHFFFAOYSA-N (2-amino-5-phenyl-1,3-thiazol-4-yl)-phenylmethanone Chemical compound C=1C=CC=CC=1C=1SC(N)=NC=1C(=O)C1=CC=CC=C1 JAWMKHVPLLQZHX-UHFFFAOYSA-N 0.000 description 3
- GBVYYYFICXVGLN-UHFFFAOYSA-N C(C1=CC=C(C=C1)OC)(=O)C=1N=C(SC1C1=CC=CC=C1)N Chemical compound C(C1=CC=C(C=C1)OC)(=O)C=1N=C(SC1C1=CC=CC=C1)N GBVYYYFICXVGLN-UHFFFAOYSA-N 0.000 description 3
- 238000006846 Hantzsch Thiazole synthesis reaction Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- YQCLOJYBGYHQBH-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C(=O)C=2N=C(SC2C2=CC=CC=C2)N)C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(C(=O)C=2N=C(SC2C2=CC=CC=C2)N)C=C1 YQCLOJYBGYHQBH-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- HUVMDVMRZUVXIK-UHFFFAOYSA-N 2-azido-1,3-diphenylprop-2-en-1-one Chemical compound C=1C=CC=CC=1C(=O)C(N=[N+]=[N-])=CC1=CC=CC=C1 HUVMDVMRZUVXIK-UHFFFAOYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229950003476 aminothiazole Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000986 disperse dye Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- KFLIQEZHQGNQAV-UHFFFAOYSA-N ethyl 2-azidohex-2-enoate Chemical compound CCCC=C(N=[N+]=[N-])C(=O)OCC KFLIQEZHQGNQAV-UHFFFAOYSA-N 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 239000011964 heteropoly acid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- NYGZLYXAPMMJTE-UHFFFAOYSA-M metanil yellow Chemical group [Na+].[O-]S(=O)(=O)C1=CC=CC(N=NC=2C=CC(NC=3C=CC=CC=3)=CC=2)=C1 NYGZLYXAPMMJTE-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
本发明公开了一种4,5-二取代-2-氨基噻唑化合物,其结构式为:;所述R1为4-甲苯基、4-氯苯基、4-甲氧基苯基、4-硝基苯基或丙氧基,R2为苯基、4-甲苯基、4-氟苯基、4-甲氧苯基、2-呋喃基、异丙基、4-硝基苯基或正丙基。本发明还同时提供了上述4,5-二取代-2-氨基噻唑化合物的制备方法,包括以下步骤:将烯烃叠氮类化合物、硫氰酸钾在溶剂和金属催化剂存在的条件下于75~85℃反应,所得的反应液浓缩后,用水和乙酸乙酯萃取,所得的有机层经洗涤后,干燥,旋转蒸发仪浓缩;所得浓缩物进行硅胶柱层析,得4,5-二取代-2-氨基噻唑化合物。The invention discloses a 4,5-disubstituted-2-aminothiazole compound, the structural formula of which is: ; The R 1 is 4-tolyl, 4-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl or propoxy, R 2 is phenyl, 4-tolyl, 4-fluoro Phenyl, 4-methoxyphenyl, 2-furyl, isopropyl, 4-nitrophenyl or n-propyl. The present invention also simultaneously provides a preparation method for the above-mentioned 4,5-disubstituted-2-aminothiazole compound, comprising the following steps: preparing an alkene azide compound and potassium thiocyanate in the presence of a solvent and a metal catalyst at 75 to 85 ° C reaction, the obtained reaction solution was concentrated, extracted with water and ethyl acetate, the obtained organic layer was washed, dried, and concentrated by a rotary evaporator; the obtained concentrate was subjected to silica gel column chromatography to obtain 4,5-disubstituted- 2-aminothiazole compounds.
Description
技术领域technical field
本发明属化合物的合成方法,主要涉及4,5-二取代-2-氨基噻唑化合物及其制备方法。The invention belongs to a synthesis method of a compound, and mainly relates to a 4,5-disubstituted-2-aminothiazole compound and a preparation method thereof.
背景技术Background technique
噻唑类化合物是一类重要的杂环化合物,在医药、农业、材料、生命科学领域均有重要的应用。氨基噻唑类化合物通过氨基官能团可发生一系列反应,由此合成的化合物在农药、染料等方面有着广泛的应用,如用于合成除草剂、单偶氮分散染料等。2-氨基噻唑类化合物广泛地用于合成治疗肿瘤、高血压等疾病的药物。Thiazole compounds are an important class of heterocyclic compounds, which have important applications in the fields of medicine, agriculture, materials, and life sciences. Aminothiazole compounds can undergo a series of reactions through the amino functional group, and the compounds thus synthesized have a wide range of applications in pesticides, dyes, etc., such as for the synthesis of herbicides, monoazo disperse dyes, etc. 2-aminothiazole compounds are widely used in the synthesis of drugs for the treatment of tumors, hypertension and other diseases.
2-氨基噻唑化合物因为具有重要的应用价值,其合成方法一直受到广泛的关注,其中最为经典的是Hantzsch等提出的噻唑合成法(Hantzsch,A.;Weber,J.H.ChemischeBerichte.1887,20,3118),它以α-卤代酮或α-卤代醛和硫脲作用,得到2-氨基噻唑类化合物(式1)。Because of the important application value of 2-aminothiazole compound, its synthesis method has been widely concerned, and the most classic one is the thiazole synthesis method proposed by Hantzsch et al. (Hantzsch, A.; Weber, J.H.ChemischeBerichte.1887, 20, 3118) , it reacts with α-halogenated ketone or α-halogenated aldehyde and thiourea to obtain 2-aminothiazole compounds (Formula 1).
但是Hantzsch噻唑合成法是在酸性条件下反应,采用极性有机溶剂,反应时间较长,产率也不是很理想。后人在Hantzsch的基础上对合成方法进行了大量改进,Biswanath等(Biswanath,D.;Reddy,V.S.JournalofMolecularCatalysisA:Chemical.2006,252,235.)用杂多酸盐AMP为催化剂进行反应;Yadav等(Yadav,J.S.;Subba;Reddy,B.V.TetraheronLetters.2008,49,231)用Cu(OTf)2催化的α-重氮酮和硫脲的反应。However, the Hantzsch thiazole synthesis method reacts under acidic conditions, adopts polar organic solvents, has a long reaction time, and the yield is not very satisfactory. Later generations have carried out a lot of improvement to synthetic method on the basis of Hantzsch, Biswanath etc. (Biswanath, D.; Reddy, VSJournalofMolecularCatalysisA:Chemical.2006,252,235.) react with heteropolyacid salt AMP as catalyst; Yadav etc. (Yadav, JS; Subba; Reddy, BV Tetraheron Letters. 2008, 49, 231) Cu(OTf) catalyzed reaction of α - diazonone and thiourea.
除了Hantzsch噻唑合成法及其改进外,Aoyama等(Aoyama,T.;Murata,S.;Arai,I.Tetrahedron,2006,62,14)报道了利用α-卤代酮以及KSCN/SiO2-NH4OAc/Al2O3载体一锅法反应得到2-氨基噻唑(式2),;Pradip等(Pradip,K.S.;Chandrasekhar,A.;Sridhar,S.;Javed,I.Tetrahedron,2008,49,1)用异硫氰酸与带酯基的炔基胺进行分子内硫杂迈克尔加成反应,得到氨基噻唑类化合物(式3)。In addition to the Hantzsch thiazole synthesis method and its improvement, Aoyama et al. (Aoyama, T.; Murata, S.; Arai, I. Tetrahedron, 2006,62,14) reported the use of α-halogenated ketones and KSCN/SiO 2 -NH 4 OAc/Al 2 O 3 supports a one-pot reaction to obtain 2-aminothiazole (Formula 2),; Pradip et al. (Pradip, KS; Chandrasekhar, A.; Sridhar, S.; Javed, I. 1) Intramolecular thia-Michael addition reaction between isothiocyanic acid and alkynyl amine with ester group to obtain aminothiazole compound (Formula 3).
尽管2-氨基噻唑的合成报道较多,但是已知的合成方法仍然存在着原料不易获得、产品收率低、对于不同官能团适用性差、操作繁琐等问题。此外,上述方法通常在噻唑4位引入烷基、芳香基、氢或者烷氧基,在噻唑环4位引入酰基或烃氧羰基的文献报道较少。Although there are many reports on the synthesis of 2-aminothiazole, the known synthesis methods still have problems such as difficult acquisition of raw materials, low product yield, poor applicability to different functional groups, and cumbersome operations. In addition, the above methods usually introduce an alkyl group, aryl group, hydrogen or alkoxy group at the 4-position of the thiazole ring, and there are few reports on the introduction of an acyl group or alkoxycarbonyl group at the 4-position of the thiazole ring.
已知的在噻唑环4位引入酰基或烃氧羰基的方法通常是将Hantzsch噻唑合成法的底物α-卤代酮改为3-卤代-1,2-丙二酮类化合物,从而在噻唑环4位引入酰基(Raihan,MustafaJ.etal.AdvancedSynthesis&Catalysis,2012,354,2251),或者将α-卤代酮改为3-卤代-2-氧代-丙酸酯类化合物在噻唑环4位引入烃氧羰基(Roppe,JeffreyR;etal.WO2007117778),但是合成所需的原料较难获得,且反应均需在高温回流条件下进行。The known method of introducing an acyl or alkoxycarbonyl group at the 4-position of the thiazole ring is usually to change the substrate α-halogenated ketone of the Hantzsch thiazole synthesis method into a 3-halogenated-1,2-propanedione compound, thereby in The 4th position of the thiazole ring introduces an acyl group (Raihan, MustafaJ. etal. Advanced Synthesis & Catalysis, 2012, 354, 2251), or the α-halogenated ketone is changed to a 3-halo-2-oxo-propionate compound in the thiazole ring 4 The introduction of alkoxycarbonyl (Roppe, JeffreyR; etal. WO2007117778), but the raw materials required for the synthesis are difficult to obtain, and the reaction needs to be carried out under high temperature reflux conditions.
发明内容Contents of the invention
本发明要解决的技术问题是提供一种4,5-二取代-2-氨基噻唑化合物及其制备方法。The technical problem to be solved by the present invention is to provide a 4,5-disubstituted-2-aminothiazole compound and a preparation method thereof.
为了解决上述技术问题,本发明提供一种4,5-二取代-2-氨基噻唑化合物,其结构式为:In order to solve the above technical problems, the present invention provides a 4,5-disubstituted-2-aminothiazole compound whose structural formula is:
所述R1为4-甲苯基、4-氯苯基、4-甲氧基苯基、4-硝基苯基或丙氧基,The R is 4 -tolyl, 4-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl or propoxy,
R2为苯基、4-甲苯基、4-氟苯基、4-甲氧苯基、2-呋喃基、异丙基、4-硝基苯基或正丙基。R2 is phenyl, 4 -tolyl, 4-fluorophenyl, 4-methoxyphenyl, 2-furyl, isopropyl, 4-nitrophenyl or n-propyl.
作为本发明的4,5-二取代-2-氨基噻唑化合物的改进:为以下任意一种:As the improvement of the 4,5-disubstituted-2-aminothiazole compound of the present invention: it is any one of the following:
4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑、4-(4-Chlorobenzoyl)-5-phenyl-2-aminothiazole,
4-(4-氯苯甲酰基)-5-(4-氟苯基)-2-氨基噻唑、4-(4-Chlorobenzoyl)-5-(4-fluorophenyl)-2-aminothiazole,
4-(4-硝基苯甲酰基)-5-(4-甲氧基苯基)-2-氨基噻唑、4-(4-nitrobenzoyl)-5-(4-methoxyphenyl)-2-aminothiazole,
4-苯甲酰基-5-(2-呋喃基)-2-氨基噻唑。4-benzoyl-5-(2-furyl)-2-aminothiazole.
本发明还同时提供了上述4,5-二取代-2-氨基噻唑化合物的制备方法,依次包括以下步骤:The present invention also provides a preparation method for the above-mentioned 4,5-disubstituted-2-aminothiazole compound, which includes the following steps in sequence:
1)、将烯烃叠氮类化合物、硫氰酸钾在溶剂和金属催化剂存在的条件下于75~85℃(较佳为80℃)反应,反应时间为11~13小时(较佳为12小时);烯烃叠氮类化合物、硫氰酸钾、金属催化剂的摩尔比为2:4:1;1), react olefin azides and potassium thiocyanate at 75-85°C (preferably 80°C) in the presence of a solvent and a metal catalyst, and the reaction time is 11-13 hours (preferably 12 hours ); the molar ratio of olefin azides, potassium thiocyanate and metal catalyst is 2:4:1;
所述烯烃叠氮类化合物的结构式为:The structural formula of the olefin azides is:
所述R1为苯基、4-甲基苯基、4-氯苯基、4-甲氧基苯基、4-硝基苯基或丙氧基,Said R is phenyl, 4 -methylphenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl or propoxy,
R2为苯基、4-甲苯基、4-氟苯基、4-甲氧苯基、2-呋喃基、异丙基、4-硝基苯基或正丙基;R is phenyl, 4 -tolyl, 4-fluorophenyl, 4-methoxyphenyl, 2-furyl, isopropyl, 4-nitrophenyl or n-propyl;
备注说明:一般而言,每0.5mmol的烯烃叠氮类化合物配用2.0~4.0ml的溶剂;Remarks: Generally speaking, 2.0-4.0ml of solvent is used for every 0.5mmol of olefin azide compound;
2)、步骤1)所得的反应液浓缩后(即,除去溶剂),先冷却至室温(15~30℃),再用水和乙酸乙酯萃取,所得的有机层(位于上层)经洗涤(用饱和食盐水洗涤)后,干燥,旋转蒸发仪浓缩(直至基本无溜出液);2), after the reaction solution obtained in step 1) is concentrated (that is, the solvent is removed), it is first cooled to room temperature (15-30° C.), then extracted with water and ethyl acetate, and the resulting organic layer (located on the upper layer) is washed (with Saturated brine), dried, and concentrated in a rotary evaporator (until there is basically no slip-out liquid);
3)、将步骤2)所得浓缩物进行硅胶柱层析,得4,5-二取代-2-氨基噻唑化合物。3) Perform silica gel column chromatography on the concentrate obtained in step 2) to obtain 4,5-disubstituted-2-aminothiazole compound.
作为本发明的4,5-二取代-2-氨基噻唑化合物的制备方法的改进:所述金属催化剂为七水合硫酸亚铁、九水合硝酸铁、氯化铜。As an improvement to the preparation method of the 4,5-disubstituted-2-aminothiazole compound of the present invention: the metal catalyst is ferrous sulfate heptahydrate, ferric nitrate nonahydrate, and copper chloride.
作为本发明的4,5-二取代-2-氨基噻唑化合物的制备方法的进一步改进:As a further improvement of the preparation method of the 4,5-disubstituted-2-aminothiazole compound of the present invention:
所述溶剂为极性溶剂或非极性溶剂;Described solvent is polar solvent or non-polar solvent;
所述极性溶剂为正丙醇、1,4-二氧六环、N,N-二甲基甲酰胺或硝基甲烷;非极性溶剂为甲苯。The polar solvent is n-propanol, 1,4-dioxane, N,N-dimethylformamide or nitromethane; the non-polar solvent is toluene.
作为本发明的4,5-二取代-2-氨基噻唑化合物的制备方法的进一步改进:步骤3)的硅胶柱层析为:洗脱液由石油醚:乙酸乙酯=2:1的体积比混合而得。As a further improvement of the preparation method of the 4,5-disubstituted-2-aminothiazole compound of the present invention: the silica gel column chromatography in step 3) is: the eluent is composed of petroleum ether:ethyl acetate=2:1 volume ratio mixed.
发明人通过FeSO4.7H2O等作为催化剂合成了结构新颖的4,5-二取代-2-氨基噻唑化合物(如式4所示),本合成方法条件温和,收率高,后处理方便,所用催化剂价格低廉污染少,所用原料易得,为高效合成4,5-二取代-2-氨基噻唑化合物提供了一种简单易行的方法。此外,本合成方法在噻唑环4位引入酰基或烃氧酰基,为构建结构新颖的具有生物活性的化合物库提供了可能,同时发现合成的化合物具有体外抑制肿瘤细胞活性,对于发现具有抗肿瘤活性的先导化合物具有重要的意义,本发明的合成方法未见文献报道。The inventor synthesized a 4,5-disubstituted-2-aminothiazole compound (as shown in formula 4) with a novel structure by using FeSO 4 .7H 2 O as a catalyst. The synthesis method has mild conditions, high yield and convenient post-treatment , the catalyst used is low in price and less polluted, and the raw materials used are easily available, which provides a simple and feasible method for efficiently synthesizing 4,5-disubstituted-2-aminothiazole compounds. In addition, this synthesis method introduces an acyl group or acyloxyacyl group at the 4-position of the thiazole ring, which provides the possibility for the construction of a compound library with novel structure and biological activity. At the same time, it is found that the synthesized compound has the activity of inhibiting tumor cells in vitro, which is helpful for the discovery of antitumor activity The lead compound of the present invention is of great significance, and the synthetic method of the present invention has not been reported in the literature.
具体而言,本发明为4,5-二取代-2-氨基噻唑化合物的合成提供一种新的方法,即将硫氰酸钾、烯烃叠氮化合物、金属催化剂(例如为FeSO4.7H2O)一锅法于75-85℃(较佳为80℃)进行环合反应,高产率(最高收率98%)得到目标化合物4,5-二取代-2-氨基噻唑化合物。Specifically, the present invention provides a new method for the synthesis of 4,5-disubstituted-2-aminothiazole compounds, that is, potassium thiocyanate, olefin azide compounds, metal catalysts (such as FeSO 4 .7H 2 O ) in a one-pot method at 75-85° C. (preferably 80° C.) for cyclization reaction to obtain the target compound 4,5-disubstituted-2-aminothiazole compound in high yield (the highest yield is 98%).
更进一步而言,本发明所提供的4,5-二取代-2-氨基噻唑化合物的合成路线如式5所示。Furthermore, the synthetic route of the 4,5-disubstituted-2-aminothiazole compound provided by the present invention is shown in formula 5.
其中R1为苯基、4-甲基苯基、4-氯苯基、4-甲氧基苯基、4-硝基苯基、丙氧基,R2为苯基、4-甲基苯基、4-氟苯基、4-甲氧基苯基、2-呋喃基、异丙基、4-硝基苯基、正丙基。Wherein R 1 is phenyl, 4-methylphenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl, propoxy, R 2 is phenyl, 4-methylbenzene 4-fluorophenyl, 4-methoxyphenyl, 2-furyl, isopropyl, 4-nitrophenyl, n-propyl.
烯烃叠氮化合物(Ⅰ)、硫氰酸钾(Ⅱ)和七水合硫酸亚铁(Ⅲ)在溶剂存在下于75-85℃(较佳为80℃)反应,得到目标物(Ⅳ),所用溶剂选用极性溶剂或非极性溶剂,所得产物通过硅胶柱层析得到纯化合物。Olefin azide compound (I), potassium thiocyanate (II) and ferrous sulfate heptahydrate (III) are reacted at 75-85°C (preferably 80°C) in the presence of a solvent to obtain the target compound (IV). A polar solvent or a non-polar solvent is selected as the solvent, and the obtained product is subjected to silica gel column chromatography to obtain a pure compound.
本发明提供的4,5-二取代-2-氨基噻唑化合物合成方法具有以下特点:The synthesis method of 4,5-disubstituted-2-aminothiazole compound provided by the invention has the following characteristics:
(1)本方法所用催化剂廉价易得,对环境污染较小;(1) The used catalyst of this method is cheap and easy to get, less to environmental pollution;
(2)反应温度温和,不需要高温回流,安全方便;(2) The reaction temperature is mild, no high-temperature reflux is required, and it is safe and convenient;
(3)产率高,大部分产物产率在85%以上。(3) The yield is high, most of the product yields are above 85%.
烯烃叠氮类化合物是一类重要的合成子,在杂环化合物的合成中应用广泛,具有反应活性高,反应速度快的特点,并且烯烃叠氮类化合物参与的反应一般比较温和。因此,本发明以硫氰酸钾、七水合硫酸亚铁、烯烃叠氮类化合物为原料,在温和条件下合成4,5-二取代-2-氨基噻唑化合物。此合成方法在75-85℃(较佳为80℃)下进行,合成方法新颖,未见文献报道;合成的化合物结构新颖,未见文献报道;合成的化合物具有体外抑制肿瘤细胞活性,为理想的抗肿瘤先导化合物。Olefin azides are an important class of synthons, which are widely used in the synthesis of heterocyclic compounds. They have the characteristics of high reactivity and fast reaction speed, and the reactions that olefin azides participate in are generally mild. Therefore, the present invention uses potassium thiocyanate, ferrous sulfate heptahydrate and olefin azide compounds as raw materials to synthesize 4,5-disubstituted-2-aminothiazole compounds under mild conditions. This synthetic method is carried out at 75-85°C (preferably 80°C). The synthetic method is novel and has no literature reports; the synthesized compound has a novel structure and has no literature reports; the synthesized compound has in vitro tumor cell inhibitory activity, which is ideal. antitumor lead compounds.
综上所述,本发明所得的4,5-二取代-2-氨基噻唑化合物的用途是抗肿瘤先导化合物。In summary, the use of the 4,5-disubstituted-2-aminothiazole compound obtained in the present invention is an anti-tumor lead compound.
具体实施方式detailed description
下面将通过实施例对本发明作进一步的说明。The present invention will be further described below through embodiment.
实施例1、4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑(m1)Embodiment 1, 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole (m1)
将1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮141.9mg(0.5mmol)、硫氰酸钾97.2mg(1mmol),加至反应瓶中,后加入CH3CH2CH2OH(正丙醇)2.0ml,七水合硫酸亚铁69.5mg(0.25mmol),加料完毕后,80℃搅拌反应12小时,TLC检测反应(石油醚:乙酸乙酯=1:1的体积比)。Add 141.9 mg (0.5 mmol) of 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one and 97.2 mg (1 mmol) of potassium thiocyanate to the reaction flask, and then add CH 3 CH 2 CH 2 OH (n-propanol) 2.0ml, ferrous sulfate heptahydrate 69.5mg (0.25mmol), after the addition, stirred at 80°C for 12 hours, TLC detection reaction (petroleum ether: ethyl acetate = 1 :1 volume ratio).
备注说明:当TLC检测显示1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮消失时,说明反应已结束。Remarks: When TLC detection shows that 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one disappears, it means that the reaction has ended.
反应结束后,浓缩除去正丙醇,冷却至室温,加入60ml水,反应液用3×20mL乙酸乙酯萃取三次,有机层(位于上层)合并后用3×30mL饱和食盐水洗涤三次,然后用无水硫酸钠(2.0g)干燥30分钟,旋转蒸发仪浓缩(直至基本上无溜出液时),得浓缩物;After the reaction was completed, concentrate to remove n-propanol, cool to room temperature, add 60ml of water, and extract the reaction solution three times with 3×20mL ethyl acetate, and wash the organic layer (at the upper layer) with 3×30mL saturated brine three times after merging, and then use Anhydrous sodium sulfate (2.0g) was dried for 30 minutes, and concentrated by a rotary evaporator (until there was basically no slip-out liquid) to obtain a concentrate;
浓缩物柱层析(石油醚:乙酸乙酯=2:1的体积比),所述柱层析的具体工艺参数如下:Concentrate column chromatography (petroleum ether: the volume ratio of ethyl acetate=2:1), the concrete process parameter of described column chromatography is as follows:
选用硅胶柱(装有30g的200-300目的硅胶)作为层析柱;Select a silica gel column (200-300 mesh silica gel equipped with 30g) as the chromatographic column;
以石油醚:乙酸乙酯=2:1作为洗脱液;流速为3mL/min;收集第30min~第40min的洗脱液;然后经旋转蒸发仪除去溶剂(即,洗脱液)后,得到产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑153.9mg,收率98%。Use petroleum ether: ethyl acetate = 2:1 as the eluent; the flow rate is 3mL/min; collect the eluate from the 30th to the 40th minute; then remove the solvent (ie, the eluent) by a rotary evaporator to obtain The product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was 153.9 mg, and the yield was 98%.
该4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑的结构式为:The structural formula of this 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole is:
Yellowsolid;mp:218.6-219.5℃;1HNMR(500MHz,DMSO)δ7.87(d,J=8.48,2H),7.54(d,J=8.47,2H),7.39(s,2H),7.30-7.24(m,5H);13CNMR(125MHz,DMSO)δ189.11,166.13,143.04,137.93,135.90,131.55,130.98,130.11,128.58,128.54,128.46,127.75;HRMS(ESI):m/zcalcdforC16H11ClN2OS[M+H]+:315.0359,found:315.0359。Yellowsolid; mp: 218.6-219.5℃; 1 HNMR (500MHz, DMSO) δ7.87(d, J=8.48, 2H), 7.54(d, J=8.47, 2H), 7.39(s, 2H), 7.30-7.24 (m,5H); 13 CNMR(125MHz,DMSO)δ189.11,166.13,143.04,137.93,135.90,131.55,130.98,130.11,128.58,128.54,128.46,127.75; HRMS (ESI):m/ zcalcdforC 16 H OS[M+H] + :315.0359,found:315.0359.
以下为不同条件的对照实验:The following are control experiments under different conditions:
对比例1-1、将80℃搅拌反应12小时改成20℃搅拌反应24小时,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑0mg,收率0%。Comparative example 1-1, the stirring reaction at 80°C for 12 hours was changed to the stirring reaction at 20°C for 24 hours, and the rest were the same as in Example 1. 0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, and the yield was 0%.
对比例1-2、将80℃搅拌反应12小时改成60℃搅拌反应18小时,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑147.6mg,收率94%。Comparative example 1-2, the stirring reaction at 80°C for 12 hours was changed to the stirring reaction at 60°C for 18 hours, and the rest were the same as in Example 1. 147.6 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 94%.
对比例1-3、将80℃搅拌反应12小时改成100℃搅拌反应9小时,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑150.7mg,收率96%。Comparative example 1-3, change the stirring reaction at 80°C for 12 hours to 100°C for 9 hours, and the rest are the same as in Example 1. 150.7 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 96%.
对比例1-4、将七水合硫酸亚铁由0.5当量改成0.1当量,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑56.5mg,收率36%。Comparative example 1-4, ferrous sulfate heptahydrate is changed into 0.1 equivalent by 0.5 equivalent, and all the other are the same as embodiment 1. 56.5 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 36%.
对比例1-5、将七水合硫酸亚铁由0.5当量改成0.3当量,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑131.9mg,收率84%。Comparative example 1-5, ferrous sulfate heptahydrate is changed into 0.3 equivalent by 0.5 equivalent, all the other are the same as embodiment 1. 131.9 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 84%.
对比例1-6、将七水合硫酸亚铁由0.5当量改成1当量,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑153.9mg,收率98%。Comparative example 1-6, ferrous sulfate heptahydrate is changed into 1 equivalent from 0.5 equivalent, all the other are the same as embodiment 1. 153.9 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 98%.
对比例1-7、用甲苯代替正丙醇,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑138.2mg,收率88%。Comparative example 1-7, replace n-propanol with toluene, all the other are the same as embodiment 1. 138.2 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 88%.
对比例1-8、用1,4-二氧六环代替正丙醇,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑149.2mg,收率95%。Comparative Examples 1-8, using 1,4-dioxane instead of n-propanol, and the rest are the same as in Example 1. 149.2 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 95%.
对比例1-9、用水代替正丙醇,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑0mg,收率0%。Comparative example 1-9, replace n-propanol with water, all the other are the same as embodiment 1. 0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, and the yield was 0%.
对比例1-10、用硝基甲烷代替正丙醇,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑146.0mg,收率93%。Comparative example 1-10, replace n-propanol with nitromethane, all the other are the same as embodiment 1. 146.0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 93%.
对比例1-11、用DMF(N,N-二甲基甲酰胺)代替正丙醇,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑138.2mg,收率88%。Comparative example 1-11, DMF (N,N-dimethylformamide) was used instead of n-propanol, and the rest were the same as in Example 1. 138.2 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 88%.
对比例1-12、用九水合硝酸铁代替七水合硫酸亚铁,摩尔量不变,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑44.0mg,收率28%。Comparative Example 1-12, ferric nitrate nonahydrate was used to replace ferrous sulfate heptahydrate, the molar weight was constant, and the rest were the same as in Example 1. 44.0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 28%.
对比例1-13、用氰化亚铜代替七水合硫酸亚铁,摩尔量不变,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑0mg,收率0%。Comparative example 1-13, replace ferrous sulfate heptahydrate with cuprous cyanide, the molar weight is constant, all the other are the same as embodiment 1. 0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, and the yield was 0%.
对比例1-14、用氯化铜代替七水合硫酸亚铁,摩尔量不变,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑65.9mg,收率42%。Comparative example 1-14, replace ferrous sulfate heptahydrate with cupric chloride, the molar weight is constant, all the other are the same as embodiment 1. 65.9 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 42%.
对比例1-15、取消催化剂的使用,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑0mg,收率0%。Comparative example 1-15, cancel the use of catalyst, all the other are the same as embodiment 1. 0 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, and the yield was 0%.
对比例1-16、将硫氰酸钾由2当量改成1当量,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑130.3mg,收率83%。Comparative example 1-16, change potassium thiocyanate from 2 equivalents to 1 equivalent, all the other are the same as embodiment 1. 130.3 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 83%.
对比例1-17、将硫氰酸钾由2当量改成3当量,其余同实施例1。得到黄色固体状产物4-(4-氯苯甲酰基)-5-苯基-2-氨基噻唑153.9mg,收率98%。Comparative example 1-17, change potassium thiocyanate from 2 equivalents to 3 equivalents, all the other are the same as embodiment 1. 153.9 mg of the product 4-(4-chlorobenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 98%.
实施例2、4-苯甲酰基-5-苯基-2-氨基噻唑(m2)Embodiment 2, 4-benzoyl-5-phenyl-2-aminothiazole (m2)
以1-苯基-2-叠氮-3-苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到黄色固体状产物4-苯甲酰基-5-苯基-2-氨基噻唑128.8mg,收率92%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 1-phenyl-2-azido-3-phenyl-2-propen-1-one, mol Quantity is constant, all the other are equal to embodiment 1. 128.8 mg of the product 4-benzoyl-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 92%.
其结构式为:Its structural formula is:
Yellowsolid;mp:160.4-160.8℃;1HNMR(500MHz,DMSO)δ7.84(d,J=7.05,2H),7.59(t,J=6.88,1H),7.47(d,J=7.31,2H),7.35-7.24(m,7H);13CNMR(125MHz,DMSO)δ190.76,166.14,143.60,137.12,133.12,131.11,129.66,128.99,128.56,128.39,128.35,127.59;HRMS(ESI):m/zcalcdforC16H12N2OS[M+H]+:281.0749,found:281.0748。Yellowsolid; mp: 160.4-160.8℃; 1 HNMR (500MHz, DMSO) δ7.84(d, J=7.05, 2H), 7.59(t, J=6.88, 1H), 7.47(d, J=7.31, 2H) ,7.35-7.24(m,7H); 13 CNMR(125MHz,DMSO) δ190.76,166.14,143.60,137.12,133.12,131.11,129.66,128.99,128.56,128.39,128.35,127.69 ; HRMS(ESI) for m/ H 12 N 2 OS[M+H] + :281.0749,found:281.0748.
实施例3、4-(4-甲基苯甲酰基)-5-苯基-2-氨基噻唑(m3)Example 3, 4-(4-methylbenzoyl)-5-phenyl-2-aminothiazole (m3)
以1-对甲基苯基-2-叠氮-3-苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到黄色固体状产物4-(4-甲基苯甲酰基)-5-苯基-2-氨基噻唑138.2mg,收率94%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene-1-one with 1-p-methylphenyl-2-azido-3-phenyl-2-propene-1-one Ketone, molar weight is constant, all the other are equal to embodiment 1. 138.2 mg of the product 4-(4-methylbenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 94%.
其结构式为:Its structural formula is:
Yellowsolid;mp:189.4-189.9℃;1HNMR(500MHz,DMSO)δ7.75(d,J=8.07,2H),7.33(s,2H),7.28-7.21(m,7H),2.35(s,3H);13CNMR(125MHz,DMSO)δ190.63,166.21,143.88,143.74,134.45,131.18,129.85,128.98,128.60,128.19,127.91,127.47,21.22;HRMS(ESI):m/zcalcdforC17H14N2OS[M+H]+:295.0905,found:295.0907。Yellowsolid; mp:189.4-189.9℃; 1 HNMR (500MHz, DMSO) δ7.75(d, J=8.07, 2H), 7.33(s, 2H), 7.28-7.21(m, 7H), 2.35(s, 3H ); 13 CNMR (125MHz, DMSO) δ190.63, 166.21, 143.88, 143.74, 134.45, 131.18, 129.85, 128.98, 128.60, 128.19, 127.91, 127.47, 21.22; HRMS (ESI): m/z2 H 14 N 17 M+H] + :295.0905, found: 295.0907.
实施例4、4-(4-甲氧基苯甲酰基)-5-苯基-2-氨基噻唑(m4)Example 4, 4-(4-methoxybenzoyl)-5-phenyl-2-aminothiazole (m4)
以1-对甲氧基苯基-2-叠氮-3-苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到黄色固体状产物4-(4-甲氧基苯甲酰基)-5-苯基-2-氨基噻唑139.5mg,收率90%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene-1 with 1-p-methoxyphenyl-2-azido-3-phenyl-2-propene-1-one -ketone, the molar weight is constant, and all the other are equal to embodiment 1. 139.5 mg of the product 4-(4-methoxybenzoyl)-5-phenyl-2-aminothiazole was obtained as a yellow solid, with a yield of 90%.
其结构式为:Its structural formula is:
Yellowsolid;mp:220.5-220.9℃;1HNMR(500MHz,DMSO)δ7.84(d,J=8.89,2H),7.35(s,2H),7.29-7.20(m,5H),7.00(d,J=8.92,2H),3.82(s,3H);13CNMR(125MHz,DMSO)δ189.66,166.25,163.32,144.08,132.15,131.25,129.64,128.61,128.05,127.36,127.10,113.76,55.56;HRMS(ESI):m/zcalcdforC17H14N2O2S[M+H]+:311.0854,found:311.0855。Yellowsolid; mp: 220.5-220.9℃; 1 HNMR (500MHz, DMSO) δ7.84(d, J=8.89, 2H), 7.35(s, 2H), 7.29-7.20(m, 5H), 7.00(d, J =8.92,2H),3.82(s,3H); 13 CNMR(125MHz,DMSO)δ189.66,166.25,163.32,144.08,132.15,131.25,129.64,128.61,128.05,127.36,127.10,113.76,55.5I6 :m/zcalcdforC 17 H 14 N 2 O 2 S[M+H] + :311.0854,found:311.0855.
实施例5、4-(4-硝基苯甲酰基)-5-(4-甲基苯基)-2-氨基噻唑(m5)Example 5, 4-(4-nitrobenzoyl)-5-(4-methylphenyl)-2-aminothiazole (m5)
以1-对硝基苯基-2-叠氮-3-对甲基苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到黄色固体状产物4-(4-硝基苯甲酰基)-5-(4-甲基苯基)-2-氨基噻唑142.4mg,收率84%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene with 1-p-nitrophenyl-2-azido-3-p-methylphenyl-2-propen-1-one -1-ketone, molar weight is constant, all the other are equal to embodiment 1. 142.4 mg of the product 4-(4-nitrobenzoyl)-5-(4-methylphenyl)-2-aminothiazole was obtained as a yellow solid, with a yield of 84%.
其结构式为:Its structural formula is:
Yellowsolid;mp:190.4-190.9℃;1HNMR(500MHz,DMSO)δ8.28(d,J=8.87,2H),8.04(d,J=8.88,2H),7.38(s,2H),7.26(d,J=8.11,2H),7.13(d,J=7.96,2H),2.27(s,3H);13CNMR(125MHz,DMSO)δ188.33,165.66,149.38,143.02,142.05,137.71,133.11,130.81,129.05,128.88,127.89,123.29,20.73;HRMS(ESI):m/zcalcdforC17H13N3O3S[M+H]+:340.0756,found:340.0758。Yellowsolid; mp: 190.4-190.9℃; 1 HNMR (500MHz, DMSO) δ8.28(d, J=8.87, 2H), 8.04(d, J=8.88, 2H), 7.38(s, 2H), 7.26(d ,J=8.11,2H),7.13(d,J=7.96,2H),2.27(s,3H); 13 CNMR(125MHz,DMSO)δ188.33,165.66,149.38,143.02,142.05,137.71,133.11,130.81,129.05 , 128.88, 127.89, 123.29, 20.73; HRMS (ESI): m/zcalcdforC 17 H 13 N 3 O 3 S[M+H] + : 340.0756, found: 340.0758.
实施例6、4-(4-氯苯甲酰基)-5-(4-氟苯基)-2-氨基噻唑(m6)Example 6, 4-(4-chlorobenzoyl)-5-(4-fluorophenyl)-2-aminothiazole (m6)
以1-对氯苯基-2-叠氮-3-对氟苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到淡黄色固体状产物4-(4-氯苯甲酰基)-5-(4-氟苯基)-2-氨基噻唑152.7mg,收率92%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene-1 with 1-p-chlorophenyl-2-azido-3-p-fluorophenyl-2-propene-1-one -ketone, the molar weight is constant, and all the other are equal to embodiment 1. 152.7 mg of the product 4-(4-chlorobenzoyl)-5-(4-fluorophenyl)-2-aminothiazole was obtained as a pale yellow solid, with a yield of 92%.
其结构式为:Its structural formula is:
Paleyellowsolid;mp:197.4-197.7℃;1HNMR(500MHz,DMSO)δ7.87(d,J=8.31,2H),7.54(d,J=8.27,2H),7.40-7.35(m,4H),7.15(t,J=8.65,2H);13CNMR(125MHz,DMSO)δ188.71,165.99,162.61,160.65,143.12,137.87,135.99,131.62,130.93,130.87,129.54,128.40,127.47,127.44,115.53,115.36;HRMS(ESI):m/zcalcdforC16H10ClFN2OS[M+H]+:333.0265,found:333.0264。Paleyellowsolid; mp: 197.4-197.7℃; 1 HNMR (500MHz, DMSO) δ7.87(d, J=8.31, 2H), 7.54(d, J=8.27, 2H), 7.40-7.35(m, 4H), 7.15 (t, J=8.65, 2H); 13 CNMR (125MHz, DMSO) δ188.71, 165.99, 162.61, 160.65, 143.12, 137.87, 135.99, 131.62, 130.93, 130.87, 129.54, 128.40, 127.443, 127.5 HR (ESI): m/z calcd for C 16 H 10 ClFN 2 OS[M+H] + : 333.0265, found: 333.0264.
实施例7、4-(4-硝基苯甲酰基)-5-(4-甲氧基苯基)-2-氨基噻唑(m7)Example 7, 4-(4-nitrobenzoyl)-5-(4-methoxyphenyl)-2-aminothiazole (m7)
以1-对硝基苯基-2-叠氮-3-对甲氧基苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到橙色固体状产物4-(4-硝基苯甲酰基)-5-(4-甲氧基苯基)-2-氨基噻唑152.7mg,收率86%。Substitute 1-p-nitrophenyl-2-azido-3-p-methoxyphenyl-2-propen-1-one for 1-p-chlorophenyl-2-azido-3-phenyl-2- Propylene-1-one, the molar weight is constant, all the other are equal to embodiment 1. 152.7 mg of the product 4-(4-nitrobenzoyl)-5-(4-methoxyphenyl)-2-aminothiazole was obtained as an orange solid, with a yield of 86%.
其结构式为:Its structural formula is:
Orangesolid;mp:217.8-218.3℃;1HNMR(500MHz,DMSO)δ8.27(d,J=8.59,2H),8.03(d,J=8.60,2H),7.33-7.32(m,4H),6.89(d,J=8.60,2H),3.74(s,3H);13CNMR(125MHz,DMSO)δ188.15,165.27,159.24,149.29,143.26,141.69,133.57,130.79,130.49,123.23,122.97,113.90,55.20;HRMS(ESI):m/zcalcdforC17H13N3O4S[M+H]+:356.0705,found:356.0708。Orangesolid; mp: 217.8-218.3℃; 1 HNMR (500MHz, DMSO) δ8.27 (d, J=8.59, 2H), 8.03 (d, J=8.60, 2H), 7.33-7.32 (m, 4H), 6.89 (d, J=8.60, 2H), 3.74 (s, 3H); 13 CNMR (125MHz, DMSO) δ188.15, 165.27, 159.24, 149.29, 143.26, 141.69, 133.57, 130.79, 130.49, 123.23, 122.97, 113.90, 5; HRMS (ESI): m/z calcd for C 17 H 13 N 3 O 4 S [M+H] + : 356.0705, found: 356.0708.
实施例8、4-(4-硝基苯甲酰基)-5-苯基-2-氨基噻唑(m8)Example 8, 4-(4-nitrobenzoyl)-5-phenyl-2-aminothiazole (m8)
以1-对硝基苯基-2-叠氮-3-苯基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到红色固体状产物4-(4-硝基苯甲酰基)-5-苯基-2-氨基噻唑130.0mg,收率80%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene-1-one with 1-p-nitrophenyl-2-azido-3-phenyl-2-propene-1-one Ketone, molar weight is constant, all the other are equal to embodiment 1. 130.0 mg of the product 4-(4-nitrobenzoyl)-5-phenyl-2-aminothiazole was obtained as a red solid, with a yield of 80%.
其结构式为:Its structural formula is:
Redsolid;mp:215.3-215.8℃;1HNMR(500MHz,DMSO)δ8.28(d,J=8.63,2H),8.04(d,J=8.60,2H),7.42(s,2H),7.37(d,J=6.89,2H),7.33-7.27(m,3H);13CNMR(125MHz,DMSO)δ188.41,166.00,149.44,142.90,142.40,132.73,130.87,130.82,129.01,128.53,128.13,123.33;HRMS(ESI):m/zcalcdforC16H11N3O3S[M+H]+:326.0599,found:326.0598。Redsolid; mp: 215.3-215.8℃; 1 HNMR (500MHz, DMSO) δ8.28(d, J=8.63, 2H), 8.04(d, J=8.60, 2H), 7.42(s, 2H), 7.37(d ,J=6.89,2H),7.33-7.27(m,3H); 13 CNMR (125MHz,DMSO)δ188.41,166.00,149.44,142.90,142.40,132.73,130.87,130.82,129.01,128.53,128.13,123.3 ESI): m/z calcd for C 16 H 11 N 3 O 3 S[M+H] + : 326.0599, found: 326.0598.
实施例9、4-苯甲酰基-5-(2-呋喃基)-2-氨基噻唑(m9)Example 9, 4-benzoyl-5-(2-furyl)-2-aminothiazole (m9)
以1-苯基-2-叠氮-3-(2-呋喃基)-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到棕色固体状产物4-苯甲酰基-5-(2-呋喃基)-2-氨基噻唑120.2mg,收率89%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propene-1 with 1-phenyl-2-azido-3-(2-furyl)-2-propene-1-one -ketone, the molar weight is constant, and all the other are equal to embodiment 1. 120.2 mg of the product 4-benzoyl-5-(2-furyl)-2-aminothiazole was obtained as a brown solid, with a yield of 89%.
其结构式为:Its structural formula is:
Brownsolid;mp:115.4-115.8℃;1HNMR(500MHz,DMSO)δ7.88(d,J=7.22,2H),7.67(d,J=0.99,1H),7.60(t,J=7.35,1H),7.50-7.47(m,4H),6.94(d,J=3.18,1H),6.53(d,J=1.51,1H);13CNMR(125MHz,DMSO)δ189.16,165.50,145.66,143.21,142.91,137.67,132.72,129.67,128.17,120.91,112.15,109.53;HRMS(ESI):m/zcalcdforC14H10N2O2S[M+H]+:271.0541,found:271.0542。Brownsolid; mp:115.4-115.8℃; 1 HNMR (500MHz, DMSO) δ7.88(d, J=7.22,2H),7.67(d,J=0.99,1H),7.60(t,J=7.35,1H) ,7.50-7.47(m,4H),6.94(d,J=3.18,1H),6.53(d,J=1.51,1H); 13 CNMR(125MHz,DMSO)δ189.16,165.50,145.66,143.21,142.91,137.67 , 132.72, 129.67, 128.17, 120.91, 112.15, 109.53; HRMS (ESI): m/z calcd for C 14 H 10 N 2 O 2 S[M+H] + : 271.0541, found: 271.0542.
实施例10、4-苯甲酰基-5-异丙基-2-氨基噻唑(m10)Example 10, 4-benzoyl-5-isopropyl-2-aminothiazole (m10)
以1-苯基-2-叠氮-3-异丙基-2-丙烯-1-酮代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到淡黄色固体状产物4-苯甲酰基-5-异丙基-2-氨基噻唑114.4mg,收率93%。Substituting 1-phenyl-2-azido-3-isopropyl-2-propen-1-one for 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one, Molar weight is constant, all the other are equal to embodiment 1. 114.4 mg of the product 4-benzoyl-5-isopropyl-2-aminothiazole was obtained as a pale yellow solid, with a yield of 93%.
其结构式为:Its structural formula is:
Paleyellowsolid;mp:115.3-115.7℃;1HNMR(500MHz,DMSO)δ7.90(d,J=7.48,2H),7.57(t,J=7.33,1H),7.47(t,J=7.58,2H),7.01(s,2H),3.71-3.63(m,1H),1.22(d,J=6.75,6H);13CNMR(125MHz,DMSO)δ189.22,163.74,145.40,142.51,138.67,132.12,129.68,127.91,27.09,24.95;HRMS(ESI):m/zcalcdforC13H14N2OS[M+H]+:247.0905,found:247.0905。Paleyellowsolid; mp: 115.3-115.7℃; 1 HNMR (500MHz, DMSO) δ7.90(d, J=7.48, 2H), 7.57(t, J=7.33, 1H), 7.47(t, J=7.58, 2H) ,7.01(s,2H),3.71-3.63(m,1H),1.22(d,J=6.75,6H); 13 CNMR(125MHz,DMSO)δ189.22,163.74,145.40,142.51,138.67,132.12,129.68,127.91 , 27.09, 24.95; HRMS (ESI): m/zcalcdforC 13 H 14 N 2 OS [M+H] + : 247.0905, found: 247.0905.
实施例11、4-丙氧羰基-5-(4-甲基苯基)-2-氨基噻唑(m11)Example 11, 4-propoxycarbonyl-5-(4-methylphenyl)-2-aminothiazole (m11)
以2-叠氮-3-对甲基苯基-丙烯酸乙酯代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余同实施例1。得到白色固体状产物4-丙氧羰基-5-(4-甲基苯基)-2-氨基噻唑131.1mg,收率95%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 2-azido-3-p-methylphenyl-ethyl acrylate, the molar weight remains the same, and the rest are the same Example 1. 131.1 mg of the product 4-propoxycarbonyl-5-(4-methylphenyl)-2-aminothiazole was obtained as a white solid, with a yield of 95%.
其结构式为:Its structural formula is:
Whitesolid;mp:123.9-124.3℃;1HNMR(500MHz,DMSO)δ7.27(d,J=7.89,2H),7.23(s,2H),7.17(d,J=7.81,2H),3.99(t,J=6.56,2H),2.31(s,3H),1.52-1.45(m,2H),0.74(t,J=7.37,3H);13CNMR(125MHz,DMSO)δ165.51,162.19,137.46,135.68,132.46,129.28,128.65,128.27,65.61,21.35,20.77,10.19;HRMS(ESI):m/zcalcdforC14H16N2O2S[M+H]+:277.1011,found:277.1015。Whitesolid; mp: 123.9-124.3℃; 1 HNMR (500MHz, DMSO) δ7.27(d, J=7.89, 2H), 7.23(s, 2H), 7.17(d, J=7.81, 2H), 3.99(t ,J=6.56,2H),2.31(s,3H),1.52-1.45(m,2H),0.74(t,J=7.37,3H); 13 CNMR(125MHz,DMSO)δ165.51,162.19,137.46,135.68, 132.46 , 129.28, 128.65, 128.27, 65.61, 21.35, 20.77, 10.19; HRMS(ESI): m/zcalcdforC14H16N2O2S[M+H]+ : 277.1011 , found :277.1015.
实施例12、4-丙氧羰基-5-(4-硝基苯基)-2-氨基噻唑(m12)Example 12, 4-propoxycarbonyl-5-(4-nitrophenyl)-2-aminothiazole (m12)
以2-叠氮-3-对硝基苯基-丙烯酸乙酯代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到黄色固体状产物4-丙氧羰基-5-(4-硝基苯基)-2-氨基噻唑145.9mg,收率83%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 2-azido-3-p-nitrophenyl-ethyl acrylate, the molar weight remains unchanged, and the rest are the same In Example 1. 145.9 mg of the product 4-propoxycarbonyl-5-(4-nitrophenyl)-2-aminothiazole was obtained as a yellow solid, with a yield of 83%.
其结构式为:Its structural formula is:
Yellowsolid;mp:153.8-154.2℃;1HNMR(500MHz,DMSO)δ8.21(d,J=8.24,2H),7.67(d,J=8.20,2H),7.55(s,2H),4.04(t,J=5.97,2H),1.53-1.49(m,2H),0.74(t,J=7.02,3H);13CNMR(125MHz,DMSO)δ167.01,161.97,146.47,138.25,137.87,130.46,128.72,123.29,66.06,21.26,10.15;HRMS(ESI):m/zcalcdforC13H13N3O4S[M+H]+:308.0705,found:308.0707。Yellowsolid; mp: 153.8-154.2℃; 1 HNMR (500MHz, DMSO) δ8.21(d, J=8.24, 2H), 7.67(d, J=8.20, 2H), 7.55(s, 2H), 4.04(t ,J=5.97,2H),1.53-1.49(m,2H),0.74(t,J=7.02,3H); 13 CNMR(125MHz,DMSO)δ167.01,161.97,146.47,138.25,137.87,130.46,128.72,123.29 , 66.06, 21.26, 10.15; HRMS (ESI): m/zcalcdforC 13 H 13 N 3 O 4 S[M+H] + : 308.0705, found: 308.0707.
实施例13、4-丙氧羰基-5-(4-甲氧基苯基)-2-氨基噻唑(m13)Example 13, 4-propoxycarbonyl-5-(4-methoxyphenyl)-2-aminothiazole (m13)
以2-叠氮-3-对甲氧基苯基-丙烯酸乙酯代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到白色固体状产物4-丙氧羰基-5-(4-甲氧基苯基)-2-氨基噻唑138.7mg,收率95%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 2-azido-3-p-methoxyphenyl-ethyl acrylate, the molar weight remains unchanged, and the rest Identical to Example 1. 138.7 mg of the product 4-propoxycarbonyl-5-(4-methoxyphenyl)-2-aminothiazole was obtained as a white solid, with a yield of 95%.
其结构式为:Its structural formula is:
Whitesolid;mp:169.5-169.9℃;1HNMR(500MHz,DMSO)δ7.32(d,J=8.55,2H),7.21(s,2H),6.92(d,J=8.61,2H),3.99(t,J=6.58,2H),3.77(s,3H),1.53-1.46(m,2H),0.75(t,J=7.37,3H);13CNMR(125MHz,DMSO)δ165.19,162.14,159.12,135.33,132.72,130.78,123.33,113.54,65.56,55.20,21.37,10.23;HRMS(ESI):m/zcalcdforC14H16N2O3S[M+H]+:293.0960,found:293.0963。Whitesolid; mp: 169.5-169.9℃; 1 HNMR (500MHz, DMSO) δ7.32(d, J=8.55, 2H), 7.21(s, 2H), 6.92(d, J=8.61, 2H), 3.99(t ,J=6.58,2H),3.77(s,3H),1.53-1.46(m,2H),0.75(t,J=7.37,3H); 13 CNMR(125MHz,DMSO)δ165.19,162.14,159.12,135.33, 132.72, 130.78, 123.33, 113.54, 65.56, 55.20, 21.37, 10.23; HRMS (ESI): m/ zcalcdforC14H16N2O3S [ M + H] + : 293.0960 ,found:293.0963.
实施例14、4-丙氧羰基-5-(2-呋喃基)-2-氨基噻唑(m14)Example 14, 4-propoxycarbonyl-5-(2-furyl)-2-aminothiazole (m14)
以2-叠氮-3-(2-呋喃基)-丙烯酸乙酯代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到棕色固体状产物4-丙氧羰基-5-(2-呋喃基)-2-氨基噻唑113.4mg,收率90%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 2-azido-3-(2-furyl)-ethyl acrylate, the molar weight remains unchanged, and the rest Identical to Example 1. 113.4 mg of the product 4-propoxycarbonyl-5-(2-furyl)-2-aminothiazole was obtained as a brown solid, with a yield of 90%.
其结构式为:Its structural formula is:
Brownsolid;mp:100.7-101.1℃;1HNMR(500MHz,DMSO)δ7.70(s,1H),7.43(s,2H),7.12(d,J=3.30,1H),6.58(s,1H),4.13(t,J=6.71,2H),1.67-1.60(m,2H),0.89(t,J=7.37,3H);13CNMR(125MHz,DMSO)δ165.32,162.07,145.36,143.04,134.93,122.82,112.28,110.83,65.92,21.54,10.30;HRMS(ESI):m/zcalcdforC11H12N2O3S[M+H]+:253.0647,found:253.0647。Brownsolid; mp: 100.7-101.1℃; 1 HNMR (500MHz, DMSO) δ7.70(s, 1H), 7.43(s, 2H), 7.12(d, J=3.30, 1H), 6.58(s, 1H), 4.13(t, J=6.71,2H),1.67-1.60(m,2H),0.89(t,J=7.37,3H); 13 CNMR(125MHz,DMSO)δ165.32,162.07,145.36,143.04,134.93,122.82, 112.28, 110.83, 65.92, 21.54, 10.30; HRMS (ESI): m/z calcd for C 11 H 12 N 2 O 3 S[M+H] + : 253.0647, found: 253.0647.
实施例15、4-丙氧羰基-5-正丙基-2-氨基噻唑(m15)Example 15, 4-propoxycarbonyl-5-n-propyl-2-aminothiazole (m15)
以2-叠氮-3-正丙基-丙烯酸乙酯代替1-对氯苯基-2-叠氮-3-苯基-2-丙烯-1-酮,摩尔量不变,其余等同于实施例1。得到白色固体状产物4-丙氧羰基-5-正丙基-2-氨基噻唑102.6mg,收率90%。Replace 1-p-chlorophenyl-2-azido-3-phenyl-2-propen-1-one with 2-azido-3-n-propyl-acrylic acid ethyl ester, the molar weight is unchanged, and the rest are equal to the implementation example 1. 102.6 mg of the product 4-propoxycarbonyl-5-n-propyl-2-aminothiazole was obtained as a white solid, with a yield of 90%.
其结构式为:Its structural formula is:
Whitesolid;mp:92.3-92.7℃;1HNMR(500MHz,DMSO)δ7.00(s,2H),4.09(t,J=6.61,2H),2.93(t,J=7.51,2H),1.68-1.61(m,2H),1.58-1.50(m,2H),0.93-0.88(m,6H);13CNMR(125MHz,DMSO)δ163.96,162.13,137.68,135.97,65.40,28.31,24.47,21.60,13.51,10.41;HRMS(ESI):m/zcalcdforC10H16N2O2S[M+H]+:229.1011,found:229.1009。Whitesolid; mp:92.3-92.7℃; 1 HNMR(500MHz,DMSO)δ7.00(s,2H),4.09(t,J=6.61,2H),2.93(t,J=7.51,2H),1.68-1.61 (m,2H),1.58-1.50(m,2H),0.93-0.88(m,6H); 13 CNMR(125MHz,DMSO)δ163.96,162.13,137.68,135.97,65.40,28.31,24.47,21.60,13.51,10.41 ; HRMS (ESI): m/z calcd for C 10 H 16 N 2 O 2 S [M+H] + : 229.1011, found: 229.1009.
抗肿瘤活性实验Antitumor Activity Experiment
实验、以A431(人表皮癌细胞)为测试细胞株,采用MTT法对上述化合物进行抗肿瘤活性评价。将受试化合物配成一定的浓度与人癌细胞株共孵后,测定其对癌细胞株的抑制率,结果见表1。In the experiment, A431 (human epidermal carcinoma cell) was used as the test cell line, and the antitumor activity of the above compounds was evaluated by the MTT method. After the test compound was formulated into a certain concentration and co-incubated with the human cancer cell line, its inhibitory rate on the cancer cell line was measured, and the results are shown in Table 1.
检测方法具体如下:The detection method is as follows:
1.收集对数期生长的A431细胞,调节细胞悬液浓度为1*104/孔;1. Collect the A431 cells grown in the logarithmic phase, and adjust the concentration of the cell suspension to 1*10 4 /well;
2.加入化合物,使该化合物的终浓度达到20umol/L;2. Add the compound so that the final concentration of the compound reaches 20umol/L;
3.37℃,5%CO2孵育44小时;3. Incubate at 37°C, 5% CO 2 for 44 hours;
4.每孔加入20ul的MTT溶液(5mg/ml,用PBS配制,pH=7.4),继续培养4小时;4. Add 20ul of MTT solution (5mg/ml, prepared in PBS, pH=7.4) to each well, and continue to incubate for 4 hours;
5.离心6min,除去上清液,加入DMSO每孔150ul,摇床低速震动10min,在酶联免疫检测仪OD570nm(630nm校准)测量各孔吸光值;5. Centrifuge for 6 minutes, remove the supernatant, add 150ul of DMSO per well, shake the shaker at low speed for 10min, and measure the absorbance of each well at OD570nm (calibrated at 630nm) of an enzyme-linked immunosorbent assay instrument;
抑制率的计算公式为:细胞抑制率=1-(加药组OD值-调零孔OD值)/(对照组OD值-调零孔OD值)。The formula for calculating the inhibition rate is: cell inhibition rate=1-(OD value of drug-dosed group-OD value of zero-adjusted well)/(OD value of control group-OD value of zero-adjusted well).
表1化合物对A431肿瘤细胞的抑制率The inhibitory rate of table 1 compound to A431 tumor cell
从表1可以看出合成的部分化合物(m1、m6、m7、m9)体外抑制肿瘤细胞活性大于对照物吉非替尼,显示合成的化合物为结构新型的抗肿瘤先导化合物,对其进一步进行结构修饰,有望发现结构新颖的抗肿瘤候选药物。It can be seen from Table 1 that some compounds synthesized (m1, m6, m7, m9) have greater antitumor cell activity in vitro than the control substance gefitinib, which shows that the synthesized compounds are novel anti-tumor lead compounds. Modifications are expected to discover novel anti-tumor drug candidates.
最后,还需要注意的是,以上列举的仅是本发明的若干个具体实施例。显然,本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。Finally, it should be noted that the above examples are only some specific embodiments of the present invention. Obviously, the present invention is not limited to the above embodiments, and many variations are possible. All deformations that can be directly derived or associated by those skilled in the art from the content disclosed in the present invention should be considered as the protection scope of the present invention.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410321285.9A CN104151262B (en) | 2014-07-07 | 2014-07-07 | 4,5-bis-replaces-thiazolamine compound and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410321285.9A CN104151262B (en) | 2014-07-07 | 2014-07-07 | 4,5-bis-replaces-thiazolamine compound and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104151262A CN104151262A (en) | 2014-11-19 |
CN104151262B true CN104151262B (en) | 2016-02-24 |
Family
ID=51876923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410321285.9A Expired - Fee Related CN104151262B (en) | 2014-07-07 | 2014-07-07 | 4,5-bis-replaces-thiazolamine compound and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104151262B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104910095B (en) * | 2015-06-29 | 2017-01-04 | 浙江大学 | The preparation method of 4-replacement-thiazolamine compound |
CN104910096B (en) * | 2015-07-01 | 2017-01-04 | 浙江大学 | 4-replaces the preparation method of-5-thiocyanogen-thiazolamine compound |
CN105524013B (en) * | 2016-02-02 | 2018-05-08 | 浙江大学 | 4,5- bis- substitutes the preparation method of -2- substituted-amino thiazolium compounds |
CN105772088B (en) * | 2016-04-06 | 2018-07-10 | 上海应用技术学院 | (S) Mn-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications |
CN105772085B (en) * | 2016-04-06 | 2018-04-13 | 上海应用技术学院 | (S) the thiourea modified Cr Anderson types heteropolyacid catalyst of 1 (1 ethoxy, 1 isopropyl), preparation method and applications |
CN105797771B (en) * | 2016-04-06 | 2018-05-15 | 上海应用技术学院 | (R) Mn-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications |
CN105772086B (en) * | 2016-04-06 | 2018-03-30 | 上海应用技术学院 | (S) the thiourea modified Mn Anderson types heteropolyacid catalyst of 1 (isopropyl of 1 ethoxy 1), preparation method and applications |
CN105833910B (en) * | 2016-04-06 | 2018-03-30 | 上海应用技术学院 | (R) the thiourea modified Cr Anderson types heteropolyacid catalyst of 1 (phenethyl of 2 hydroxyl 1), preparation method and applications |
CN105772102B (en) * | 2016-04-06 | 2018-05-15 | 上海应用技术学院 | (R) Mn-Anderson types heteropolyacid catalyst thiourea modified -1- (1- (2- naphthyls) ethyl), preparation method and applications |
CN105833911B (en) * | 2016-04-06 | 2018-03-09 | 上海应用技术学院 | The Cr Anderson types heteropolyacid catalyst of 1 Phenethylthiourea modification, preparation method and applications |
CN105854941B (en) * | 2016-04-06 | 2018-07-10 | 上海应用技术学院 | (S) Cr-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications |
CN105665019B (en) * | 2016-04-06 | 2018-03-02 | 上海应用技术学院 | (S) the thiourea modified Mn Anderson types heteropolyacid catalyst of 1 (phenylpropyl of 3 hydroxyl 1), preparation method and applications |
CN108947930A (en) * | 2018-07-19 | 2018-12-07 | 浙江大学 | The synthetic method of bis- substitution -2- amino-thiazol compound of 4,5- |
CN109265411A (en) * | 2018-11-08 | 2019-01-25 | 武汉轻工大学 | 4- hydroxyl-3- substitution-thiazolidine -2 -one class compound preparation method |
CN110117263B (en) * | 2019-06-11 | 2020-12-25 | 湖南中医药大学 | 2-amino-5-acyl thiazole derivative and synthetic method thereof |
CN115215817B (en) * | 2022-07-06 | 2023-09-19 | 武汉工程大学 | A kind of 2-aminothiazole-4-acetic acid derivative and its preparation method and use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049337A (en) * | 1989-08-07 | 1991-02-20 | 藤泽药品工业株式会社 | Thiazole derivative prepares their method, and the medicinal compositions that contains them |
-
2014
- 2014-07-07 CN CN201410321285.9A patent/CN104151262B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049337A (en) * | 1989-08-07 | 1991-02-20 | 藤泽药品工业株式会社 | Thiazole derivative prepares their method, and the medicinal compositions that contains them |
Non-Patent Citations (3)
Title |
---|
Facile, efficient synthesis of polyfunctionalized 2-aminoimidazoles via vinyl azides and cyanamide;S. Liu,et al.;《Tetrahedron》;20140109;第70卷;全文 * |
Preparation and Spectral Characterization of Substituted 2-Aminothiazoles;George Y. S,et al;《Journal of Chemical and Engineering Data》;19731231;第18卷(第1期);全文 * |
SYNTHESIS AND PURINE P2X RECEPTOR ANTAGONIST ACTIVITY OF THIAZOLE DERIVATIVES;A. U. Ziganshin et al.;《Pharmaceutical Chemistry Journal》;20051231;第39卷(第6期);第304页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104151262A (en) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104151262B (en) | 4,5-bis-replaces-thiazolamine compound and preparation method thereof | |
TWI697494B (en) | Synthesis of copanlisib and its dihydrochloride salt | |
CN108409625A (en) | A kind of preparation method of 2-pyrrolidone compounds | |
CN105524013B (en) | 4,5- bis- substitutes the preparation method of -2- substituted-amino thiazolium compounds | |
CN105820174B (en) | A kind of preparation method of polysubstituted thiophene diindyl derivative | |
CN115894288B (en) | A kind of synthetic method of imine compound | |
CN104016929B (en) | A kind of method for synthesizing quinazoline-4 (3H)-ketone | |
CN109265403B (en) | A kind of synthetic method of benzimidazole and derivative thereof | |
CN109608493B (en) | A kind of method for preparing α-phosphoramidate compound | |
CN104119319B (en) | Containing the pyrimidine derivatives and its production and use of 1,2,3-triazole and urea structure uint | |
CN108341789B (en) | Synthetic method of 4,5-disubstituted-2-aminothiazole compounds | |
CN106349172B (en) | Method for efficiently preparing quinazolinone compound | |
CN110698422A (en) | A kind of synthetic method of arylmercaptodiazole derivatives | |
CN113307780B (en) | A kind of preparation method of 2-amino-1,3,4-oxadiazole compound and its prepared compound | |
CN110857299B (en) | Synthesis method of 3-thiocyanoimidazo [1,5-a ] quinoline compound | |
CN108912124A (en) | A method of utilizing the ionic liquid-catalyzed preparation compound of pyrazole heterocycle containing sulfuryl | |
CN103275008B (en) | 3,4, 5-trisubstituted pyrazole compound and preparation method thereof | |
CN105237473B (en) | The 4,5,6 multifunctional amino nicotinic acid nitrile derivatives of dough 2 and preparation method | |
CN105732526A (en) | 1,4,5-tri-substituted-1,2,3-triazole derivative and preparation method thereof | |
CN102532052B (en) | Thiazole amine compound and synthesis thereof | |
CN113200902B (en) | Polysubstituted pyrrole derivative and preparation method thereof | |
CN105111220A (en) | Substituted 1,4-dihydro-chromene [2, 3-b] pyrrole compound and preparation method thereof | |
Wu et al. | An environmentally friendly solvent-free synthesis of 3, 4-dihydropyrimidinones using ap-aminobenzene sulfonic acid catalyzed Biginelli reaction | |
CN117229181A (en) | Preparation method of methylsulfonylamino chalcone derivative | |
CN106565582A (en) | Penta-substituted pyrrole compound and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160224 Termination date: 20160707 |
|
CF01 | Termination of patent right due to non-payment of annual fee |